^
Association details:
| Biomarker: | TP53 D281E |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab
Published date:
10/30/2017
Excerpt:
The patient presented in this study responded successfully to the p53MVA/pembrolizumab administration with the generation of p53-specific T cell responses directed against wild type p53 epitopes...TP53 genomic alterations identified in this patient included D281E missense and R209fs* deletion/frameshift mutations.
DOI:
10.1080/2162402X.2017.1363138
Trial ID:
